Pharmaceutical and medical device companies are collecting more gender identity data than ever — in clinical trials, patient support programs, and direct-to-patient marketing. The goal is usually admirable: improve representation, meet regulatory expectations, or build trust with diverse patient groups. But the way that data is handled can quickly become a liability.
Under modern privacy frameworks, gender identity is classified as sensitive data. That means improper collection, storage, or use can trigger fines, lawsuits, reputational damage, and even investor scrutiny. For companies regulated by the FDA, those risks also intersect with advertising rules, research integrity, and fraud oversight. A privacy misstep can escalate into a full-blown business crisis.
Regulatory risks are piling up from multiple directions. The European Union’s General Data Protection Regulation applies to some activities originating inside the United States. GDPR explicitly protects “special categories” of personal data, including health, sexual orientation, and biometric data. The EU generally recognizes that a person can express a gender identity different from the one assigned at birth. Failing to accurately record that identity — or processing assigned sex when it is not relevant — would typically be seen as inconsistent with GDPR’s data accuracy principle.
In the U.S., a growing number of states have their own privacy laws. California’s CPRA expanded the CCPA to cover “sensitive personal information,” which includes sexual orientation and related identity markers. Consumers can limit use of that data to only what is “necessary” to deliver expected services. California’s attorney general has been aggressive on enforcement. Virginia, Colorado, and more than a dozen other states have adopted similar laws. Companies operating in multiple jurisdictions could face scrutiny from several regulators at once.
Related: Medspa Industry Faces New Regulatory Challenges
Fines under CCPA can reach $7,500 per violation. GDPR fines can go up to 4 percent of global turnover.
Beyond privacy law, antidiscrimination laws also apply. Companies that collect gender identity data for inclusion tracking and later reuse it for targeted marketing without consent are opening themselves up to claims of profiling, not just privacy violations. Vendors may repurpose the data for unrelated analytics. Courts and regulators are increasingly viewing such actions as discrimination, not sloppy data management.
Business consequences go well beyond regulatory fines
Litigation exposure is growing. Privacy claims are often bundled with discrimination and emotional distress allegations. Class actions can demand wide discovery, pulling in vendor contracts and internal emails. Settlements often happen just to avoid reputational damage, even when the company believes it did nothing wrong.
Reputational fallout can be severe. Stories about companies mishandling gender identity data attract significant media coverage. In clinical research, subjects are supposed to be anonymized.
Related: Who is at fault for an injury caused by a slip-and-fall accident?
As data collection expands, life sciences companies are finding that what was once a niche compliance concern has become a mainstream risk. Regulators, plaintiffs’ lawyers, and advocacy groups are all paying closer attention. The margin for error is shrinking, and the cost of getting it wrong is rising fast.
Investor and board scrutiny is also intensifying. In M&A or private equity due diligence, weak gender identity data governance can be flagged as a material risk. Whistleblowers or employee advocates may raise red flags that disrupt deals or trigger post-closing disputes.
Practical steps to reduce the risk
Best practices start with treating gender identity data like medical or biometric information. Companies should map where the data flows, classify it as high-risk, and obtain explicit consent for collection and any secondary use, especially marketing.
Access controls matter. They should compartmentalize data, log access, and use anonymization or encryption where possible. Vendor contracts need to limit use, enforce deletion timelines, and permit audits. Those obligations should flow down to subcontractors.
Related: Why You Should Never Ignore a License Suspension Notice
Participants should be able to update their gender identity data. Offering nonbinary or self-describe options allows accurate recording. Privacy notices need clear language on why they collect the data and how they share it.
Regular audits and data protection impact assessments that specifically evaluate gender identity data risks are essential. Training for clinical, marketing, and IT teams on sensitive data risks should be ongoing. A privacy governance committee with oversight over gender identity data can help keep the issue on leadership’s radar.
For life sciences companies, mishandling gender identity data is more than a privacy problem. With regulators, plaintiffs’ attorneys, and investors watching closely, it becomes a trust problem. And trust is hard to rebuild once it’s lost.
